Regulatory – Page 24

23 August, 2013

Regulatory

NeuroVive: Interim Report 1 Jan. 2013 till 30 Jun. 2013

Milestones achieved consolidate positioning in mitochondrial medicine Six months (1 Jan. 2013 - 30 Jun. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 863,000 (31 ...

12 June, 2013

Regulatory

NeuroVive signs collaboration agreement with Isomerase Therapeutics and receives the first milestone payment from Sihuan

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics to develop the molecules that were recently acquired from ...

5 June, 2013

Regulatory

First patient recruited to clinical phase II study for treatment of traumatic brain injury

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company ́s drug candidate NeuroSTAT® for the ...

24 May, 2013

Regulatory

NeuroVive: Interim report 1 Jan. 2013 till 31 Mar. 2013

The listing on Nasdaq OMX creates possibilities for the future

Abliva

Press releases

NeuroVive: Interim Report 1 Jan. 2013 till 30 Jun. 2013

NeuroVive signs collaboration agreement with Isomerase Therapeutics and receives the first milestone payment from Sihuan

First patient recruited to clinical phase II study for treatment of traumatic brain injury

NeuroVive: Interim report 1 Jan. 2013 till 31 Mar. 2013